FDA Needs Four More Weeks to Review MannKind's Diabetes Drug

by Web Master, Benzinga Editor
December 28, 2010 9:49 AM | 4 seconds read |

The FDA has requested four additional weeks to review MannKind's experimental drug Afrezza.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!